Ojjaara (Momelotinib Dihydrochloride) Patent Expiration, LOE Window & CMS Spending

Ojjaara (Momelotinib Dihydrochloride) by GSK: FDA Orange Book core substance LOE 2035-06-11 (last listed 2040-12-02), 0 AB generics, $351.7M 2024 CMS Part D & Medicaid spend, and $26,900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN216873 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-06-11
Last Listed Patent or Exclusivity Date2040-12-02
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$351.7M
2024 Medicare Part D Spend$341.7M
2024 Medicaid Spend$10.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($26,900 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.